Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for AMRX

Stock Name	Amneal Pharmaceuticals, Inc. Class A Common Stock
Ticker	AMRX(USD) NYSE
TYPE	Common Stock
Country	USA
ISIN	US03168L1052
LEI	549300VV176ZO5WQHZ61

Show aggregate AMRX holdings

News associated with AMRX

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) Given New $14.00 Price Target at JPMorgan Chase & Co.: AMNEAL PHARMACEUTICALS (NASDAQ:AMRX – Get Free Report) had its price target upped by JPMorgan Chase & Co. from $12.00 to $14.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 45.68% […] - 2025-09-18 02:24:44
Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts: (RTTNews) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives. Amylyx Pharmaceuticals, Amneal Pharmaceuticals, and argenx SE each marked notable gains on Septe - 2025-09-11 06:41:22
AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) EVP Nikita Shah Sells 114,492 Shares of Stock: AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Get Free Report) EVP Nikita Shah sold 114,492 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $9.66, for a total transaction of $1,105,992.72. Following the completion of the transaction, the executive vice president directly owned 152,743 shares of […] - 2025-08-26 05:24:51
Andrew Boyer Sells 279,244 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) EVP Andrew Boyer sold 279,244 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the transaction, the executive vice president owned 152,426 shares in the […] - 2025-08-25 05:07:01
3,685 Shares in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) Acquired by Headlands Technologies LLC: Headlands Technologies LLC purchased a new position in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,685 shares of the company’s stock, valued at approximately $31,000. Other hedge funds have also recently added […] - 2025-08-14 04:56:57
Zurcher Kantonalbank Zurich Cantonalbank Buys 13,464 Shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX): Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Free Report) by 30.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,276 shares of the company’s stock after buying an additional 13,464 shares during the quarter. […] - 2025-08-08 04:56:48
Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $11.60: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus rating of “Buy” by the five brokerages that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued ratings on the stock […] - 2025-07-29 02:48:58
Jennison Associates LLC Purchases New Position in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX): Jennison Associates LLC purchased a new stake in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 71,426 shares of the company’s stock, valued at approximately $599,000. A number of other institutional investors and hedge funds have […] - 2025-07-23 06:20:55
Massachusetts Financial Services Co. MA Has $1.40 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Massachusetts Financial Services Co. MA reduced its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 2.2% during the 1st quarter, HoldingsChannel.com reports. The firm owned 167,168 shares of the company’s stock after selling 3,810 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Amneal Pharmaceuticals were worth $1,401,000 at […] - 2025-07-21 05:52:49
Janney Montgomery Scott LLC Purchases 4,100 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Janney Montgomery Scott LLC increased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 26.9% in the 1st quarter, Holdings Channel reports. The fund owned 19,350 shares of the company’s stock after buying an additional 4,100 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Amneal Pharmaceuticals were worth $162,000 as of […] - 2025-07-07 04:20:50
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $11.60 Average Price Target from Analysts: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus recommendation of “Buy” by the five brokerages that are currently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock […] - 2025-07-04 02:00:54
Assenagon Asset Management S.A. Has $6.87 Million Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Assenagon Asset Management S.A. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 7.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 819,736 shares of the company’s stock after purchasing an additional 59,267 shares during the period. Assenagon Asset Management S.A. […] - 2025-06-15 05:43:09
California State Teachers Retirement System Acquires 12,282 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): California State Teachers Retirement System grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 10.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,713 shares of the company’s stock after purchasing an additional 12,282 shares during the period. […] - 2025-06-11 05:36:45
Two Sigma Advisers LP Has $347,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Two Sigma Advisers LP lessened its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 42.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 43,849 shares of the company’s stock after selling 32,400 shares during the quarter. Two Sigma Advisers LP’s holdings in […] - 2025-06-06 05:09:03
Amneal Pharma Recalls USP 400 Mg/80 Mg Sulfamethoxazole/Trimethoprim Tablets: (RTTNews) - Amneal Pharmaceutical LLC, a unit of Amneal Pharmaceuticals, Inc., is recalling three lots of Sulfamethoxazole and Trimethoprim Tablets, USP, 400 mg/80 mg, to the consumer level due to potential microbial contamination, according to the U.S. Food and Drug Administrati - 2025-06-05 08:37:42
Squarepoint Ops LLC Increases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Squarepoint Ops LLC grew its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 540.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 124,744 shares of the company’s stock after purchasing an additional 105,268 shares during the period. Squarepoint Ops LLC’s holdings in Amneal Pharmaceuticals were worth $988,000 as of its most recent […] - 2025-06-01 05:31:01
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 2,911 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,460 shares of the company’s stock after buying an additional […] - 2025-05-28 04:50:51
Northern Trust Corp Raises Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Northern Trust Corp increased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 9.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,777,283 shares of the company’s stock after acquiring an additional 156,699 shares during the quarter. Northern Trust Corp’s holdings in Amneal Pharmaceuticals were worth $14,076,000 at the end of […] - 2025-05-16 04:23:00
Amneal Pharmaceuticals (NASDAQ:AMRX) Downgraded by StockNews.com to “Buy”: StockNews.com lowered shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday morning. A number of other analysts also recently issued reports on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and […] - 2025-05-14 04:58:47
Price T Rowe Associates Inc. MD Raises Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Price T Rowe Associates Inc. MD boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 11.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 97,250 shares of the company’s stock after buying an additional 9,704 shares during the quarter. […] - 2025-05-12 05:18:52
Voya Investment Management LLC Has $384,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Voya Investment Management LLC cut its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,488 shares of the company’s stock after selling 3,442 shares during the period. Voya […] - 2025-05-11 06:06:55
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Upgraded by StockNews.com: Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Monday. A number of other equities analysts have also recently weighed in on the stock. Barclays upped their price target on shares of Amneal Pharmaceuticals from $10.00 […] - 2025-05-07 03:06:47
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Dimensional Fund Advisors LP: Dimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 5.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,991,702 shares of the company’s stock after acquiring an additional 278,653 shares during the quarter. […] - 2025-05-05 05:18:54
Raymond James Financial Inc. Invests $2.95 Million in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Raymond James Financial Inc. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 371,996 shares of the company’s stock, valued at approximately $2,946,000. Several other institutional investors also recently added to or reduced […] - 2025-04-29 05:05:11
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.80 Consensus PT from Analysts: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has earned a consensus recommendation of “Buy” from the five analysts that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last […] - 2025-04-22 02:20:56
Wellington Management Group LLP Sells 8,577 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Wellington Management Group LLP trimmed its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 10.4% in the fourth quarter, HoldingsChannel reports. The firm owned 74,019 shares of the company’s stock after selling 8,577 shares during the quarter. Wellington Management Group LLP’s holdings in Amneal Pharmaceuticals were worth $586,000 as of its […] - 2025-04-15 05:32:51
Federated Hermes Inc. Purchases 5,849 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Federated Hermes Inc. lifted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 271,834 shares of the company’s stock after buying an additional 5,849 shares during the period. […] - 2025-04-14 05:15:03
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Arrowstreet Capital Limited Partnership: Arrowstreet Capital Limited Partnership reduced its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 25.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,541,058 shares of the company’s stock after selling 527,921 shares during the […] - 2025-04-06 05:27:00
Swiss National Bank Acquires 31,900 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Swiss National Bank lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 13.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 274,000 shares of the company’s stock after purchasing an additional 31,900 shares during the quarter. Swiss National Bank’s […] - 2025-03-28 05:54:50
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Principal Financial Group Inc.: Principal Financial Group Inc. grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 9.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 96,835 shares of the company’s stock after purchasing an additional 8,213 shares during the quarter. Principal Financial Group Inc.’s holdings in Amneal Pharmaceuticals were worth $767,000 as […] - 2025-03-07 06:21:06

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) AMRX holdings

Date	Number of AMRX Shares Held	Base Market Value of AMRX Shares	Local Market Value of AMRX Shares	Change in AMRX Shares Held	Change in AMRX Base Value	Current Price per AMRX Share Held	Previous Price per AMRX Share Held
2025-11-11 (Tuesday)	205,032	USD 2,450,132	USD 2,450,132	0	USD 96,365	USD 11.95	USD 11.48
2025-11-10 (Monday)	205,032	USD 2,353,767	USD 2,353,767	525	USD 28,522	USD 11.48	USD 11.37
2025-11-07 (Friday)	204,507	USD 2,325,245	USD 2,325,245	0	USD -59,307	USD 11.37	USD 11.66
2025-11-06 (Thursday)	204,507	USD 2,384,552	USD 2,384,552	525	USD 2	USD 11.66	USD 11.69
2025-11-05 (Wednesday)	203,982	USD 2,384,550	USD 2,384,550	0	USD 69,354	USD 11.69	USD 11.35
2025-11-04 (Tuesday)	203,982	USD 2,315,196	USD 2,315,196	527	USD 37,517	USD 11.35	USD 11.195
2025-11-03 (Monday)	203,455	USD 2,277,679	USD 2,277,679	0	USD 76,296	USD 11.195	USD 10.82
2025-10-31 (Friday)	203,455	USD 2,201,383	USD 2,201,383	0	USD 166,833	USD 10.82	USD 10
2025-10-30 (Thursday)	203,455	USD 2,034,550	USD 2,034,550	2,635	USD -60,003	USD 10	USD 10.43
2025-10-29 (Wednesday)	200,820	USD 2,094,553	USD 2,094,553	1,056	USD 38,981	USD 10.43	USD 10.29
2025-10-28 (Tuesday)	199,764	USD 2,055,572	USD 2,055,572	0	USD 7,991	USD 10.29	USD 10.25
2025-10-27 (Monday)	199,764	USD 2,047,581	USD 2,047,581	0	USD -59,929	USD 10.25	USD 10.55

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of AMRX by Blackrock for IE00BDZVHG35

Show aggregate share trades of AMRX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 525 11.620 11.381 11.405 USD 5,987 8.39
2025-11-06 BUY 525 11.880 11.605 11.632 USD 6,107 8.35
2025-11-04 BUY 527 11.400 10.940 10.986 USD 5,790 8.30
2025-10-30 BUY 2,635 10.700 9.990 10.061 USD 26,511 8.25
2025-10-29 BUY 1,056 10.430 10.450 10.448 USD 11,033 8.24
2025-10-22 SELL -2,108 10.430 10.485 10.479 USD -22,091 8.16 Loss of -4,886 on sale
2025-10-20 BUY 1,054 10.240 10.280 10.276 USD 10,831 8.13
2025-10-17 BUY 2,632 9.920 9.930 9.929 USD 26,133 8.12
2025-10-15 BUY 4,192 9.780 9.870 9.861 USD 41,337 8.11
2025-10-03 BUY 3,626 10.390 10.675 10.647 USD 38,604 8.08
2025-10-02 BUY 518 10.400 10.455 10.449 USD 5,413 8.06
2025-09-30 BUY 1,036 10.010 10.135 10.123 USD 10,487 8.02
2025-09-26 BUY 1,036 9.750 9.885 9.872 USD 10,227 8.00
2025-09-25 BUY 1,038 9.600 9.690 9.681 USD 10,049 7.98
2025-09-18 BUY 547 9.810 9.825 9.823 USD 5,373 7.97
2025-09-17 BUY 1,647 9.610 9.840 9.817 USD 16,169 7.96
2025-07-17 SELL -1,094 8.240 8.305 8.299 USD -9,079 7.94 Loss of -393 on sale
2025-07-16 BUY 3,291 8.260 8.310 8.305 USD 27,332 7.94
2025-07-11 SELL -4,304 8.330 8.380 8.375 USD -36,046 7.93 Loss of -1,932 on sale
2025-07-02 BUY 29,590 8.370 8.420 8.415 USD 249,000 7.91
2025-06-25 BUY 1,076 8.050 8.135 8.127 USD 8,744 7.90
2025-06-20 BUY 5,889 7.820 8.030 8.009 USD 47,165 7.90
2025-06-11 BUY 1,038 7.780 7.950 7.933 USD 8,234 7.90
2025-06-10 BUY 1,038 7.810 8.049 8.025 USD 8,330 7.90
2025-06-04 SELL -520 7.210 7.500 7.471 USD -3,885 7.92 Profit of 235 on sale
2025-04-23 BUY 519 7.300 7.440 7.426 USD 3,854 8.16
2025-04-10 SELL -4,144 6.970 7.220 7.195 USD -29,816 8.32 Profit of 4,659 on sale
2025-04-08 SELL -518 6.990 7.420 7.377 USD -3,821 8.36 Profit of 510 on sale
2025-04-07 SELL -518 7.210 7.510 7.480 USD -3,875 8.38 Profit of 469 on sale
2025-04-04 SELL -2,595 7.380 7.660 7.632 USD -19,805 8.40 Profit of 2,005 on sale
2025-04-01 BUY 4,851 8.230 8.435 8.415 USD 40,819 8.41
2025-03-31 SELL -1,530 8.380 8.575 8.555 USD -13,090 8.41 Loss of -217 on sale
2025-03-21 BUY 6,734 8.660 9.000 8.966 USD 60,377 8.40
2025-03-14 SELL -7,824 8.750 8.950 8.930 USD -69,868 8.35 Loss of -4,507 on sale
2025-03-07 SELL -976 8.900 8.995 8.985 USD -8,770 8.28 Loss of -690 on sale
2025-03-04 SELL -488 8.840 9.015 8.998 USD -4,391 8.22 Loss of -381 on sale
2025-02-25 BUY 978 8.500 8.510 8.509 USD 8,322 8.14
2025-02-19 SELL -488 7.850 7.950 7.940 USD -3,875 8.18 Profit of 118 on sale
2025-02-13 BUY 1,461 7.910 7.925 7.924 USD 11,576 8.29
2025-02-12 BUY 487 7.820 7.945 7.933 USD 3,863 8.32
2025-02-11 BUY 1,948 7.960 8.030 8.023 USD 15,629 8.35
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	525	11.620	11.381	11.405	USD 5,987	8.39
2025-11-06	BUY	525	11.880	11.605	11.632	USD 6,107	8.35
2025-11-04	BUY	527	11.400	10.940	10.986	USD 5,790	8.30
2025-10-30	BUY	2,635	10.700	9.990	10.061	USD 26,511	8.25
2025-10-29	BUY	1,056	10.430	10.450	10.448	USD 11,033	8.24
2025-10-22	SELL	-2,108	10.430	10.485	10.479	USD -22,091	8.16 Loss of -4,886 on sale
2025-10-20	BUY	1,054	10.240	10.280	10.276	USD 10,831	8.13
2025-10-17	BUY	2,632	9.920	9.930	9.929	USD 26,133	8.12
2025-10-15	BUY	4,192	9.780	9.870	9.861	USD 41,337	8.11
2025-10-03	BUY	3,626	10.390	10.675	10.647	USD 38,604	8.08
2025-10-02	BUY	518	10.400	10.455	10.449	USD 5,413	8.06
2025-09-30	BUY	1,036	10.010	10.135	10.123	USD 10,487	8.02
2025-09-26	BUY	1,036	9.750	9.885	9.872	USD 10,227	8.00
2025-09-25	BUY	1,038	9.600	9.690	9.681	USD 10,049	7.98
2025-09-18	BUY	547	9.810	9.825	9.823	USD 5,373	7.97
2025-09-17	BUY	1,647	9.610	9.840	9.817	USD 16,169	7.96
2025-07-17	SELL	-1,094	8.240	8.305	8.299	USD -9,079	7.94 Loss of -393 on sale
2025-07-16	BUY	3,291	8.260	8.310	8.305	USD 27,332	7.94
2025-07-11	SELL	-4,304	8.330	8.380	8.375	USD -36,046	7.93 Loss of -1,932 on sale
2025-07-02	BUY	29,590	8.370	8.420	8.415	USD 249,000	7.91
2025-06-25	BUY	1,076	8.050	8.135	8.127	USD 8,744	7.90
2025-06-20	BUY	5,889	7.820	8.030	8.009	USD 47,165	7.90
2025-06-11	BUY	1,038	7.780	7.950	7.933	USD 8,234	7.90
2025-06-10	BUY	1,038	7.810	8.049	8.025	USD 8,330	7.90
2025-06-04	SELL	-520	7.210	7.500	7.471	USD -3,885	7.92 Profit of 235 on sale
2025-04-23	BUY	519	7.300	7.440	7.426	USD 3,854	8.16
2025-04-10	SELL	-4,144	6.970	7.220	7.195	USD -29,816	8.32 Profit of 4,659 on sale
2025-04-08	SELL	-518	6.990	7.420	7.377	USD -3,821	8.36 Profit of 510 on sale
2025-04-07	SELL	-518	7.210	7.510	7.480	USD -3,875	8.38 Profit of 469 on sale
2025-04-04	SELL	-2,595	7.380	7.660	7.632	USD -19,805	8.40 Profit of 2,005 on sale
2025-04-01	BUY	4,851	8.230	8.435	8.415	USD 40,819	8.41
2025-03-31	SELL	-1,530	8.380	8.575	8.555	USD -13,090	8.41 Loss of -217 on sale
2025-03-21	BUY	6,734	8.660	9.000	8.966	USD 60,377	8.40
2025-03-14	SELL	-7,824	8.750	8.950	8.930	USD -69,868	8.35 Loss of -4,507 on sale
2025-03-07	SELL	-976	8.900	8.995	8.985	USD -8,770	8.28 Loss of -690 on sale
2025-03-04	SELL	-488	8.840	9.015	8.998	USD -4,391	8.22 Loss of -381 on sale
2025-02-25	BUY	978	8.500	8.510	8.509	USD 8,322	8.14
2025-02-19	SELL	-488	7.850	7.950	7.940	USD -3,875	8.18 Profit of 118 on sale
2025-02-13	BUY	1,461	7.910	7.925	7.924	USD 11,576	8.29
2025-02-12	BUY	487	7.820	7.945	7.933	USD 3,863	8.32
2025-02-11	BUY	1,948	7.960	8.030	8.023	USD 15,629	8.35

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of AMRX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	128,304	0	276,453	46.4%
2025-09-18	84,920	2	339,784	25.0%
2025-09-17	212,962	356	1,209,139	17.6%
2025-09-16	171,320	0	858,517	20.0%
2025-09-15	137,651	900	623,719	22.1%
2025-09-12	184,338	0	511,689	36.0%
2025-09-11	285,899	0	863,265	33.1%
2025-09-10	312,090	2,332	713,093	43.8%
2025-09-09	176,268	0	644,091	27.4%
2025-09-08	148,566	168	605,997	24.5%
2025-09-05	142,923	180	484,350	29.5%
2025-09-04	165,588	505	550,061	30.1%
2025-09-03	139,669	0	381,499	36.6%
2025-09-02	139,721	196	368,790	37.9%
2025-08-29	183,822	2,418	590,728	31.1%
2025-08-28	242,890	2,454	455,052	53.4%
2025-08-27	74,729	8	259,403	28.8%
2025-08-26	72,643	0	230,433	31.5%
2025-08-25	86,286	0	386,365	22.3%
2025-08-22	114,252	592	435,734	26.2%
2025-08-21	100,965	0	367,166	27.5%
2025-08-20	156,423	8,528	563,148	27.8%
2025-08-19	158,774	0	368,812	43.1%
2025-08-18	104,865	20	289,047	36.3%
2025-08-15	203,126	13,258	759,207	26.8%
2025-08-14	193,411	50	1,025,464	18.9%
2025-08-13	224,302	630	780,005	28.8%
2025-08-12	250,538	2,388	961,891	26.0%
2025-08-11	228,360	0	562,600	40.6%
2025-08-08	266,139	25	980,455	27.1%
2025-08-07	138,963	0	399,270	34.8%
2025-08-06	163,112	100	526,605	31.0%
2025-08-05	217,927	236	790,771	27.6%
2025-08-04	139,352	0	453,247	30.7%
2025-08-01	252,606	0	447,322	56.5%
2025-07-31	234,789	0	522,442	44.9%
2025-07-30	95,757	1,100	474,135	20.2%
2025-07-29	92,912	4,582	607,307	15.3%
2025-07-28	118,506	0	514,015	23.1%
2025-07-25	80,697	554	439,031	18.4%
2025-07-24	80,774	184	230,230	35.1%
2025-07-23	110,575	0	264,096	41.9%
2025-07-22	74,176	300	288,608	25.7%
2025-07-21	205,971	521	736,263	28.0%
2025-07-18	122,886	132	289,582	42.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE